KR102942706B1 - 에스트로겐 수용체 분해 활성을 갖는 신규한 크로만 유도체 및 이의 용도 - Google Patents

에스트로겐 수용체 분해 활성을 갖는 신규한 크로만 유도체 및 이의 용도

Info

Publication number
KR102942706B1
KR102942706B1 KR1020227023616A KR20227023616A KR102942706B1 KR 102942706 B1 KR102942706 B1 KR 102942706B1 KR 1020227023616 A KR1020227023616 A KR 1020227023616A KR 20227023616 A KR20227023616 A KR 20227023616A KR 102942706 B1 KR102942706 B1 KR 102942706B1
Authority
KR
South Korea
Prior art keywords
piperidine
dione
piperazine
compound
oxoisoindolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227023616A
Other languages
English (en)
Korean (ko)
Other versions
KR20220118460A (ko
Inventor
지에 판
이민 치안
웨이 헤
케 리우
Original Assignee
액큐타 바이오테크놀로지 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 액큐타 바이오테크놀로지 인코포레이티드 filed Critical 액큐타 바이오테크놀로지 인코포레이티드
Publication of KR20220118460A publication Critical patent/KR20220118460A/ko
Application granted granted Critical
Publication of KR102942706B1 publication Critical patent/KR102942706B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020227023616A 2019-12-12 2020-04-13 에스트로겐 수용체 분해 활성을 갖는 신규한 크로만 유도체 및 이의 용도 Active KR102942706B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962947213P 2019-12-12 2019-12-12
US62/947,213 2019-12-12
PCT/US2020/027895 WO2021118629A1 (en) 2019-12-12 2020-04-13 Novel chroman derivatives having estrogen receptor degradation activity and uses thereof

Publications (2)

Publication Number Publication Date
KR20220118460A KR20220118460A (ko) 2022-08-25
KR102942706B1 true KR102942706B1 (ko) 2026-03-20

Family

ID=70289288

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227023616A Active KR102942706B1 (ko) 2019-12-12 2020-04-13 에스트로겐 수용체 분해 활성을 갖는 신규한 크로만 유도체 및 이의 용도

Country Status (11)

Country Link
US (2) US10800770B1 (enExample)
EP (2) EP3835298B1 (enExample)
JP (2) JP7662639B2 (enExample)
KR (1) KR102942706B1 (enExample)
CN (2) CN115003295B (enExample)
CA (1) CA3164202A1 (enExample)
DK (1) DK3835298T3 (enExample)
ES (1) ES2986594T3 (enExample)
FI (1) FI3835298T3 (enExample)
MX (1) MX2022007155A (enExample)
WO (1) WO2021118629A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
EP3932922A4 (en) 2019-02-25 2022-05-11 ShanghaiTech University SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE
WO2021023233A1 (zh) 2019-08-05 2021-02-11 上海科技大学 Egfr蛋白降解剂及其抗肿瘤应用
WO2021041348A1 (en) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
CN115003295B (zh) * 2019-12-12 2025-05-06 冰洲石生物科技公司 具有雌激素受体降解活性的新型色满衍生物及其用途
CN116234803B (zh) * 2019-12-23 2026-06-30 冰洲石生物科技公司 用于治疗癌症的雌激素受体降解剂和细胞周期蛋白依赖性激酶抑制剂的组合
AU2021226514B2 (en) * 2020-02-25 2023-10-19 Shanghaitech University Glutarimide skeleton-based compounds and application thereof
AU2021342287A1 (en) 2020-09-14 2023-04-13 Arvinas Operations, Inc. Crystalline forms of a compound for the targeted degradation of estrogen receptor
US12655135B2 (en) 2021-02-04 2026-06-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Benzo seven-membered ring bifunctional compound and application thereof
WO2022187588A1 (en) * 2021-03-04 2022-09-09 The Regents Of The University Of Michigan Small molecule degraders of estrogen receptor with cereblon ligands
JP2024512544A (ja) * 2021-03-29 2024-03-19 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 テトラヒドロナフタレン系化合物、その製造方法及びその医薬的応用
KR20240040769A (ko) 2021-07-26 2024-03-28 아비나스 오퍼레이션스, 인코포레이티드 이작용성 화합물을 제조하는 방법
JP2024539269A (ja) * 2021-10-22 2024-10-28 グルータクス セラピューティクス （シャンハイ） カンパニー、リミテッド Ｃｒｂｎ ｅ３リガーゼリガンド化合物、当該リガンド化合物に基づいて開発したタンパク質分解剤及びそれらの応用
CN113816927B (zh) * 2021-11-23 2022-02-25 苏州国匡医药科技有限公司 一种arv-471中间体的制备方法
US12662467B2 (en) 2022-04-18 2026-06-23 BioThery X, Inc. Isoindolinones, pharmaceutical compositions, and therapeutic applications
CN117229286A (zh) 2022-06-14 2023-12-15 海创药业股份有限公司 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途
US20260000676A1 (en) * 2022-07-12 2026-01-01 The Regents Of The University Of Michigan Chroman derivatives as estrogen receptor degraders
CN116751186B (zh) * 2022-12-23 2024-10-18 南京知和医药科技有限公司 一种雌激素受体调节剂的制备及其用途
CN120615091A (zh) * 2023-01-16 2025-09-09 正大天晴药业集团股份有限公司 取代的苯并七元环化合物及其应用
CN119258223A (zh) * 2023-07-06 2025-01-07 海创药业股份有限公司 一种降解雌激素受体的联合用药物及其用途
WO2025245408A1 (en) 2024-05-22 2025-11-27 Accutar Biotechnology Inc. Chroman-based compounds for treating cancer
WO2026138908A1 (zh) * 2024-12-24 2026-07-02 海创药业股份有限公司 一种雌激素受体降解剂中间体及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020049198A1 (en) 2000-09-21 2002-04-25 Littman Bruce H. Methods for treating osteoarthritis using an estrogen agonist / antagonist
US20090325930A1 (en) 2002-12-26 2009-12-31 Shinichi Hamaoka Selective estrogen receptor modulator

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4772397A (en) * 1996-10-28 1998-05-22 Novo Nordisk A/S Novel (cis)-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
AU4772297A (en) * 1996-10-28 1998-05-22 Novo Nordisk A/S Novel (cis)-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US20010021710A1 (en) * 1996-10-28 2001-09-13 Poul Jacobsen Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
WO2003063859A1 (en) * 2002-01-14 2003-08-07 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
WO2003063659A1 (de) 2002-02-01 2003-08-07 Danny Bellens Ablageständer
SG183257A1 (en) * 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
JP6768711B2 (ja) * 2015-05-26 2020-10-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 複素環式エストロゲン受容体モジュレーター及びその使用
HK1257296A1 (zh) * 2016-07-12 2019-10-18 Accutar Biotechnology Inc. 新的化合物及其用途
IL266842B (en) * 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
CN115003295B (zh) * 2019-12-12 2025-05-06 冰洲石生物科技公司 具有雌激素受体降解活性的新型色满衍生物及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020049198A1 (en) 2000-09-21 2002-04-25 Littman Bruce H. Methods for treating osteoarthritis using an estrogen agonist / antagonist
US20090325930A1 (en) 2002-12-26 2009-12-31 Shinichi Hamaoka Selective estrogen receptor modulator

Also Published As

Publication number Publication date
JP7662639B2 (ja) 2025-04-15
US20210221802A1 (en) 2021-07-22
CN115003295A (zh) 2022-09-02
FI3835298T3 (fi) 2024-07-29
EP4420728A3 (en) 2024-10-30
CN120665056A (zh) 2025-09-19
WO2021118629A1 (en) 2021-06-17
EP4420728A2 (en) 2024-08-28
KR20220118460A (ko) 2022-08-25
MX2022007155A (es) 2022-10-07
JP2025081364A (ja) 2025-05-27
CN115003295B (zh) 2025-05-06
JP2023506155A (ja) 2023-02-15
US11261178B2 (en) 2022-03-01
CA3164202A1 (en) 2021-06-17
US10800770B1 (en) 2020-10-13
ES2986594T3 (es) 2024-11-12
DK3835298T3 (da) 2024-07-29
EP3835298A1 (en) 2021-06-16
EP3835298B1 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
JP7662639B2 (ja) エストロゲン受容体分解活性を有する新規クロマン誘導体およびその使用
JP7650316B2 (ja) テトラヒドロ－１Ｈ－ピリド［３，４－ｂ］インドール抗エストロゲン薬物
EP3675839B1 (en) Novel compounds having estrogen receptor alpha degradation activity and uses thereof
JP7307796B2 (ja) アンドロゲン受容体分解活性を有する新規の置換キノリン－８－カルボニトリル誘導体およびその使用
CN114761003B (zh) 具有雄激素受体降解活性的新型脲类及其用途
WO2021061644A1 (en) Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof
KR20180095564A (ko) 벤조피페리딘 유도체, 이의 제조 방법 및 이의 의학적 용도
HUE031248T2 (en) New bicyclic pyridinones
KR20190039125A (ko) 신규한 화합물 및 이의 용도
WO2020117894A1 (en) Isocarbostyril alkaloids and functionalization thereof
CN116438177B (zh) 靶向嵌合化合物、含其的药物组合物及其制备方法和用途
HK40115205A (en) Novel chroman derivatives having estrogen receptor degradation activity and uses thereof
HK40080061A (en) Novel chroman derivatives having estrogen receptor degradation activity and uses thereof
HK40080061B (en) Novel chroman derivatives having estrogen receptor degradation activity and uses thereof
WO2025263500A1 (ja) アミノ酸誘導体
HK40058838A (en) Novel compounds having estrogen receptor alpha degradation activity and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)